These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 12824911)

  • 41. Expression of p53 and glutathione S-transferase-pi relates to clinical drug resistance in non-small cell lung cancer.
    Nakanishi Y; Kawasaki M; Bai F; Takayama K; Pei XH; Takano K; Inoue K; Osaki S; Hara N; Kiyohara C
    Oncology; 1999 Nov; 57(4):318-23. PubMed ID: 10575319
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tumour stage, node stage, p53 gene status, and bcl-2 protein expression as predictors of tumour response to platin-fluorouracil chemotherapy in patients with squamous-cell carcinoma of the head and neck.
    Fouret P; Temam S; Charlotte F; Lacau-St-Guily J
    Br J Cancer; 2002 Dec; 87(12):1390-5. PubMed ID: 12454767
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer.
    Mohamed S; Yasufuku K; Hiroshima K; Nakajima T; Yoshida S; Suzuki M; Sekine Y; Shibuya K; Iizasa T; Farouk A; Fujisawa T
    Cancer; 2007 Jun; 109(12):2506-14. PubMed ID: 17487846
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
    Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
    Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Overexpression of bax associated with mutations in the loop-sheet-helix motif of p53.
    Huang C; Kohno N; Inufusa H; Kodama K; Taki T; Miyake M
    Am J Pathol; 1999 Sep; 155(3):955-65. PubMed ID: 10487853
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.
    Sun JM; Han J; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2011 Aug; 6(8):1392-9. PubMed ID: 21716147
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic value of survivin expression in stage III non-small cell lung cancer patients treated with platinum-based therapy.
    Cho HJ; Kim HR; Park YS; Kim YH; Kim DK; Park SI
    Surg Oncol; 2015 Dec; 24(4):329-34. PubMed ID: 26690822
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Upregulation of survivin in non-small cell lung cancer and its clinicopathological correlation with p53 and Bcl-2].
    Han PH; Li XJ; Qin H; Yao J; DU N; Ren H
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2009 Aug; 25(8):710-3. PubMed ID: 19664395
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Expression profiling-based subtyping identifies novel non-small cell lung cancer subgroups and implicates putative resistance to pemetrexed therapy.
    Hou J; Lambers M; den Hamer B; den Bakker MA; Hoogsteden HC; Grosveld F; Hegmans J; Aerts J; Philipsen S
    J Thorac Oncol; 2012 Jan; 7(1):105-14. PubMed ID: 22134068
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Expression of ERCC1, MSH2 and PARP1 in non-small cell lung cancer and prognostic value in patients treated with platinum-based chemotherapy.
    Xie KJ; He HE; Sun AJ; Liu XB; Sun LP; Dong XJ
    Asian Pac J Cancer Prev; 2014; 15(6):2591-6. PubMed ID: 24761869
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bcl-2 expression in non-small cell lung cancers: higher frequency of expression in squamous cell carcinomas with earlier pT status.
    Dosaka-Akita H; Katabami M; Hommura H; Fujioka Y; Katoh H; Kawakami Y
    Oncology; 1999 Apr; 56(3):259-64. PubMed ID: 10202283
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor.
    Lee JS; Yoon A; Kalapurakal SK; Ro JY; Lee JJ; Tu N; Hittelman WN; Hong WK
    J Clin Oncol; 1995 Aug; 13(8):1893-903. PubMed ID: 7636531
    [TBL] [Abstract][Full Text] [Related]  

  • 53. c-MET/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas.
    Tsuta K; Kozu Y; Mimae T; Yoshida A; Kohno T; Sekine I; Tamura T; Asamura H; Furuta K; Tsuda H
    J Thorac Oncol; 2012 Feb; 7(2):331-9. PubMed ID: 22198430
    [TBL] [Abstract][Full Text] [Related]  

  • 54. NFV, an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell lines.
    Yang Y; Ikezoe T; Nishioka C; Bandobashi K; Takeuchi T; Adachi Y; Kobayashi M; Takeuchi S; Koeffler HP; Taguchi H
    Br J Cancer; 2006 Dec; 95(12):1653-62. PubMed ID: 17133272
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma.
    Izquierdo MA; van der Zee AG; Vermorken JB; van der Valk P; Beliën JA; Giaccone G; Scheffer GL; Flens MJ; Pinedo HM; Kenemans P
    J Natl Cancer Inst; 1995 Aug; 87(16):1230-7. PubMed ID: 7563169
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Associations between TS, TTF-1, FR-α, FPGS, and overall survival in patients with advanced non-small-cell lung cancer receiving pemetrexed plus carboplatin or gemcitabine plus carboplatin as first-line chemotherapy.
    Grønberg BH; Lund-Iversen M; Strøm EH; Brustugun OT; Scott H
    J Thorac Oncol; 2013 Oct; 8(10):1255-64. PubMed ID: 24457236
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer.
    Kawasaki M; Nakanishi Y; Kuwano K; Yatsunami J; Takayama K; Hara N
    Clin Cancer Res; 1997 Jul; 3(7):1195-200. PubMed ID: 9815799
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reduced miR-3127-5p expression promotes NSCLC proliferation/invasion and contributes to dasatinib sensitivity via the c-Abl/Ras/ERK pathway.
    Sun Y; Chen C; Zhang P; Xie H; Hou L; Hui Z; Xu Y; Du Q; Zhou X; Su B; Gao W
    Sci Rep; 2014 Oct; 4():6527. PubMed ID: 25284075
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer.
    Si J; Zhang P; Tian D; Wang X; Ma Y; Zhang J; Wang L; Yang Y
    World J Surg Oncol; 2017 Jan; 15(1):34. PubMed ID: 28129775
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
    Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
    Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.